Some preclinical trials have reported Kirsten rat sarcoma virus (KRAS)-mutant tumors with high levels of free circulating IGF-1 in patients, and several reports have suggested that KRAS mutation has varying significance on the effect of IGF-1R inhibition, depending on the tumor type and/or molecular context. This evidence concerns the gene KRAS and neoplasm.